Pioneering Fabry Disease Research at Monash University Malaysia
6 November 2023
In the realm of medical research, the pursuit of understanding and combating rare genetic disorders stands as a beacon of hope for those affected by these lesser-known conditions. As the scientific community delves into the intricate intricacies of such ailments, remarkable stories unfold within laboratories worldwide.
In the research laboratory led by Dr Kumaran Narayanan from the Jeffrey Cheah School of Medicine and Health Sciences at Monash University Malaysia, a dedicated team is delving into the intricate realms of Fabry disease, a relatively uncommon genetic disorder. Spearheading this effort are two PhD candidates from Monash University Malaysia’s School of Science, Clerance Cheong and Lucas Liew.
Personal stories and experiences often kindle the flames of dedication in the research world. However, for Clerance and Lucas, their motivation transcends personal anecdotes. They are propelled forward by a shared vision: the vision of transforming the lives of individuals and families grappling with Fabry disease.
Fabry disease is a rare genetic disorder caused by the deficiency of an enzyme called α-GAL A, leading to the accumulation of a lipid known as globotriaosylceramide (Gb3) within the body's cells. This accumulation can result in severe health complications for those affected. The breakthrough that sets Dr Narayanan's lab apart is their innovative use of Caenorhabditis elegans, a tiny nematode worm, as a model organism for their research.
Clerance's research focuses on unravelling the interaction between the human α-GAL A protein and the GANA-1 protein found in C. elegans. Her groundbreaking discovery suggests that GANA-1 may possess a limited capability to mitigate the accumulation of Gb3 in Fabry cells. This finding holds the potential to influence future approaches to Fabry disease treatments, offering a glimmer of hope to patients and their families.
Simultaneously, Lucas collaborates with Clerance to explore parallels between GANA-1-deficient C. elegans and the clinical manifestations observed in Fabry disease patients. Their collaborative efforts aim to establish C. elegans as a valuable model for comprehending the mechanisms underlying this complex genetic disorder.
The power of collaboration
Research, especially in rare genetic disorders, is not a solitary endeavour. Dr Narayanan's team has partnered with institutions like the University of British Columbia and Monash Research Platform in Australia to develop essential resources that have propelled their work forward.
These collaborations have enriched their research, providing new perspectives and tools to tackle the challenges posed by Fabry disease. It's a testament to the power of teamwork in advancing medical research.
Looking ahead, the potential implications of Dr Narayanan's lab's work bring forth a renewed sense of optimism for studies on rare diseases. While their immediate focus is characterising the GANA-1 enzyme and understanding its effectiveness in human Fabry disease cells, the long-term goal is developing novel therapeutic strategies. These strategies will then undergo rigorous preclinical and clinical trials to deliver safe and effective treatments for Fabry disease.
However, the path from scientific discovery to practical therapies is not a sprint; it's a marathon. This transformative journey is likely to span a decade or more.
The challenges faced during the team's research journey have made them more resilient and adaptable. Adapting to the unique biology of C. elegans, they persevered through difficulties by modifying protocols, exploring alternative genetic strategies, and seeking guidance from collaborators. These experiences underscore the vital role of flexibility in scientific research and the value of collaboration with experts in C. elegans biology and Fabry disease.
Importantly, their discoveries in Fabry disease hold the potential to illuminate the path toward understanding other genetic disorders within the lysosomal storage disease (LSD) family, such as Pompe's disease and Niemann-Pick disease. The impact of their work extends beyond Fabry disease, offering hope to a broader spectrum of medical research.